Familial Chylomicronemia Syndrome

Disease State Hub

Featured

Research Summary
Research Summary
01/20/2025
Miranda Manier, BA
A phase 3 clinical trial demonstrates the efficacy of olezarsen in reducing plasma triglycerides and acute pancreatitis episodes in patients with familial chylomicronemia syndrome.
01/20/2025
FDA Alert
FDA Alert
01/13/2025
Miranda Manier, BA
Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome (FCS), earning...
01/13/2025
Dermatology
Dermatology
02/09/2018
Here is a series of 4 case reports pertaining to dermatologic disorders.
02/09/2018

Interactive Features

Pop Quiz
Pop Quiz
01/07/2015
Miranda Manier, BA
A new study sheds light on olezarsen's potential to address a critical problem in a rare genetic disorder. Can you pinpoint the mechanism it targets to reduce plasma triglyceride levels? Take our quiz to...
01/07/2015